Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2014-04-25

Clinical Trial Update: Melphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

Results from a Phase 1/2 trial evaluating the combination of melphalan and panobinostat (LBH589) in patients with recurrent multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Melphalan (Melphalan)
  • Panobinostat (Panobinostat)

Snippet

Sponsor: Oncotherapeutics | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2014-04-25